PEG-hemoglobin: Effects on tumor oxygenation and radiosensitization

Radiation Oncology Investigations

Volumn 4, Issue 5, 1996, Pages 200-210

  Teicher, Beverly A ^a   Ara, Gulshan ^a   Chen, Ying Nan ^a   Emi, Yasunori ^a   Kakeji, Yoshihiro ^a   Ikebe, Masahiko ^a   Maehara, Yoshihiko ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

blood substitute radiosensitization; oxygen delivery; PEG hemoglobin; tumor hypoxia

Indexed keywords

HEMOGLOBIN; MACROGOL;

ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; DERIVATIZATION; HEMODILUTION; HYPOXIA; NONHUMAN; OXYGEN AFFINITY; OXYGEN CONSUMPTION; OXYGEN TENSION; OXYGENATION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION; RAT; TUMOR GROWTH; TUMOR VOLUME;

EID: 0030513076     PISSN: 10657541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6823(1996)4:5<200::AID-ROI2>3.0.CO;2-1     Document Type: Article

References (73)

1. Dewhirst MW: Angiogenesis and blood flow. In Teicher BA (ed): Drug Resistance in Oncology. New York: Marcel Dekker, pp 3-24, 1993.
2. Kennedy KA, Teicher BA, Rockwell SA, Sartorelli AC: The hypoxic tumor cell: A target for selective cancer chemotherapy. Biochem Pharmacol 29:1-8, 1980.
3. Sartorelli AC: Therapeutic attack of hypoxic cells of solid tumors: Presidential address. Cancer Res 48:775-778, 1988.
4. Teicher BA, Lazo JS, Sartorelli AC: Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 41:73-81, 1981.
5. Vaupel P: Oxygenation of solid tumors. In Teicher BA (ed): Drug Resistance in Oncology. New York: Marcel Dekker, pp 53-85, 1993.
6. Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 49:6449-6465, 1989.
7. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, Broder GJ: Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of therapy. Int J Radiat Oncol Biol Phys 14:831-838, 1988.
8. Gullino PM: In vivo utilization of oxygen and glucose by neoplastic tissue. Adv Exp Med Biol 75:521-536, 1975.
9. 2 by perfluorochemicals and carbogen. Int J Radiat Oncol Biol Phys 13:569-574, 1987.
10. Jain RK: Determinants of tumor blood flow: A review. Cancer Res 48:2641-2658, 1988.
11. Siemann DW, Keng PC: Characterization of radiation resistant hypoxic cell subpopulations in KHT sarcomas. (ii) Cell sorting. Br J Cancer 58:296-300, 1988.
12. 2 and radiosensitivity of tumors by Fluosol-DA (20%) and carbogen. Cancer Res 47:442-446, 1987.
13. Vaupel P, Fortmeyer HP, Runkel S, Kallinowski F: Blood flow, oxygen consumption and tissue oxygenation of human breast cancer xenografts in nude rats. Cancer Res 47:3496-3503, 1987.
14. Vaupel P, Frinak S, Bicher HI: Heterogeneous oxygen partial pressure and pH distribution C3H mouse mammary adenocarcinoma. Cancer Res 41:2008-2013, 1981.
15. Keyes SR, Rockwell S, Sartorelli AC: Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro. Cancer Res 45:3642-3645, 1985.
16. Teicher BA, Crawford JM, Holden SA, Cathcart KNS: Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity. Cancer Res 47:5036-5041, 1987.
17. Teicher BA, Holden SA, Jacobs JL: Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. Cancer Res 47:513-518, 1987.
18. Teicher BA, Holden SA, Rose CM: Effect of oxygen on the cytotoxicity and antitumor activity of etoposide. J Natl Cancer Inst 75:1129-1133, 1985.
19. Teicher BA, McIntosh-Lowe NL, Rose CM: Effect of various oxygenation conditions and Fluosol-DA on cancer chemotherapeutic agents. Biomater Artif Cells Immobil Biotech 16:533-546, 1988.
20. Teicher BA, Waxman DJ, Holden SA, Wang Y, Clarke L, Alvarez Sotomayor E, Jones SM, Frei III E; Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N′,N″-triethylenethiphosphoramide. Cancer Res 49:4996-5001, 1989.
21. Mottram JC, Eidinow A: On the effect of anemia on the reactions of skin and of tumors to radium exposure. Br J Surg 19:481-487, 1932.
22. Gaehtgens P, Kreutz P, Albrecht KH: Optimal hematocrit for canine skeletal muscle during rhythmic isotomic exercise. Eur J Appl Physiol 41:27-39, 1979.
23. Halmagyi DFJ, Goodman AH: Vascular resistance and oxygen transport as functions of hematocrit. Resuscitation 3:165-170, 1974.
24. Hirst DG: Oxygen delivery to tumors. Int J Radiat Oncol Biol Phys 180:281-291, 1986.
25. Hirst DG, Hazlehurst JL, Brown JM: The effect of hematocrit on tumour sensitivity to X-rays. Int J Radiat Biol 46:345-354, 1984.
26. 2 availability during hemodilution. Adv Exp Med Biol 180:281-291, 1984.
27. Hewitt HB, Blake E: Effect of induced host anemia on the viability and radiosensitivity of murine malignant cells in vivo. Br J Cancer 25:323-336, 1971.
28. Sutherland R, Rasey J, Hill R: Tumor biology. Am J Clin Oncol 11(3):253-74, 1988.
29. Vaupel P: oxygenation of human tumors. Strahlenther Onkol 166:377-386, 1990.
30. Chang TMS: Attempts to find a method to prepare artificial hemoglobin corpuscles. Biomater Artif Cells Artif Organs 16:1-11, 1988.
31. Chang TMS: Blood substitutes based on modified hemoglobin prepared by encapsulation or crosslinking: An overview. Biomater Artif Cells Immobil Biotech 20(2-4):159-179, 1992.
32. Chang TMS: Red blood cell substitutes: Microencapsulated hemoglobin and cross-lined hemoglobin including pyridoxylated polyhemoglobin and conjugated hemoglobin. Biomater Artif Cells Immobil Biotech 16:11-29, 1988.
33. Breepel PM, Kreuzer F, Hazevoet M: Interactions of organic phosphates with bovine hemoglobin: I. Oxylabile and phosphate-labile proton binding. Pflugers Arch 389:219-225, 1981.
34. Bunn HF: Differences in the interaction of 2,3-diphosphoglycerate with certain mammalian hemoglobins. Science 172:1049-1050, 1971.
35. Cochen A, Das Gupta TK, DeWoskin R, Moss GS: Immunologic properties of stroma vs. stroma-free hemoglobin solution. J Surg Oncol 4:19-28, 1974.
36. Cunnington PG, Jenkins SN, Tam SC, Wong JT: Oxygen-binding and immunological properties of complexes between dextran and animal hemoglobins. Biochem J 193:261-266, 1981.
37. Laver MD, Jackson E, Scherperel M, Tung C, Radford EP: Hemoglobin-O2 affinity regulation; DPF, monovalent ions, and hemoglobin concentration. J Appl Physiol 43:632-642, 1977.
38. Rapoport S, Guest GM: Distribution of acid-soluble phosphorous in the blood cells of various vertebrates. J Biol Chem 138:269-280, 1941.
39. Veldscholte J, Voorhorst-Ogink M, Bolt-deVries J, vanRooij H, Trapman J, Mulder E: Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: High affinity for progestagenic and estrogenic steroids. Biochem Biophys Acta 1052:187-194, 1990.
40. Viau A, Abuchowski A, McCoy J, Kazo G, Davis F: Toxicologic studies of a conjugate of asparaginase and polyethylene glycol in mice, rats and dogs. Am J Vet Res 47(6):1398-401, 1986.
41. Nucci ML, Shorr R, Abuchowski A: The therapeutic value of poly(ethylene glycol)-modified proteins. Adv Drug Deliv Rev 6:133-151, 1991.
42. Fuertges F, Abuchowski A: The clinical efficacy of polyethylene glycol-modified proteins. J Controlled Release 11:139-148, 1990.
43. Davis F, Abuchowski A, Van Es T: Enzyme-polyethylene glycol adducts:modified enzymes with unique properties. Enzyme Eng 4:169-173, 1978.
44. Davis S, Abuchowski A, Park Y: Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin Exp Immunol 46:649-652, 1981.
45. Abuchowski A, Kazo GM, Verhoest Jr. CR: Cancer therapy with chemically modified enzymes: Anti-tumor properties of PEG-LASP conjugates. Cancer Biochem Biophys 7:175-185, 1984.
46. Hershfield MS, Buckley RH, Greenberg ML: Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 310:589-596, 1987.
47. Keating MJ, Holmes R, Lerner S, Ho DH: L-asparaginase and PEG asparaginase - past, present, and future. Leuk. Lymphoma 10, suppl:153-157, 1993.
48. Labrude P, Mouelle P, Menu P: Hemoglobin solutions coupled with polyethylene glycol 1900: preparation, purification, quality control and pharmacological trials by hemorrhagic shock. Int. J Artif Orgfans 11:393-402, 1988.
49. Teicher BA, Dupuis NP, Liu F, Robinson MF, Menon K: Administration of a hemoglobin solution decreases hypoxia and increases radiation response in a rat mammary carcinoma. Drug Dev Res 34:231-240, 1995.
50. Teicher BA, Holden SA, Eder JP, Herman TS, Antman KH, Frei III E: Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination. Semin Oncol 17(1 [suppl 3]): 18-32, 1990.
51. Teicher BA, Rose CM: Perfluorochemical emulsions can increase tumor radiosensitivity. Science 223:934-936, 1984.
52. Teicher BA, Holden SA, Northey D, Dewhirst MW, Herman TS: Therapeutic effect of infused Fluosol-DA/ carbogen with ephedrine, flunarizine or nitroprusside. Int J Radiat Oncol Biol Phys 26:103-109, 1993.
53. Teicher BA, Dupuis NP, Holden SA, Schwartz GN, Lester S, Frei E III: Definition and manipulation of tumor oxygenation. Radiat Oncol Invest 2(2):66-76, 1994.
54. Teicher BA, Schwartz GN, Alvarez Sotomayor E, Robinson MF, Dupuis NP, Menon K: Oxygenation of tumors by a hemoglobin solution. J Cancer Res Clin Oncol 120:85-90, 1993.
55. Teicher BA, Holden SA, Dupuis NP, Kusumoto T, Liu M, Liu F, Menon K: Oxygenation of the rat 9L gliosarcoma and the rat 13762 mammary carcinoma with various doses of a hemoglobin solution. Immob Biotech 22:827-833, 1994.
56. Teicher BA, Schwartz GN, Dupuis NP, Kusumoto T, Liu M, Liu F, Northey D: Oxygenation of human tumor xenografts in nude mice by a perfluorochemical emulsion and carbogen breathing. Art Cells Blood Subs Immob Biotech 22(4):1369-1375, 1994.
57. Teicher BA, Alvarez Sotomayor E, Dupuis N, Kusumoto T, Menon K: Reduced oxygenation in a rat mammary carcinoma after chemo- or radiation therapy and reoxygenation with perflubron emulsion/carbogen breathing. J Cancer Res Clin Oncol 120(10):593-598, 1994.
58. Fleckenstein W, Jungblut JR, Suckfull M: Distribution of oxygen pressure in the periphery and centre of malignant head and neck tumours. Berlin: Blackwell Ueberreuter Wissenchaft, 81-90, 1990.
59. 2 tension measurements. Cancer Res 51:6098-6102, 1981.
60. 2-histography. Int J Radiat Oncol Biol Phys 19:953-961, 1990.
61. Sevick EM, Jain RK: Geometric resistance to blood flow in solid tumors perfused ex vivo: Effects of tumor size and perfusion pressure. Cancer Res 49:3513-3519, 1989.
62. 2-Histograph Kimoc/Sigma. In Ehrly AM, Fleckenstein W, Hauss J and Huch R (eds): Clinical Oxygen Pressure Measurement. Berlin: Blackwell Ueberreuter Wissenschaft, pp 25-29, 1990.
63. 2 tension measurements in a murine fibrosarcoma. Radiat Res 120:477-493, 1989.
64. 2 tension measurements. Cancer Res 51:3316-3322, 1991.
65. Lartigau E, Le Ridant A-M, Lambin P, Weger P, Martin L, Sigal R, Lusinchi A, Luboinski B, Eschwege F, Guichard M: Oxygenation of head and neck tumors. Cancer 71:2319-2325, 1993.
66. Martin L, Lartigau E, Weeger P, Labin P, Le Ridant AM, Lusinchi A, Wibault P, Eschwege F, Luboinski B, Guichard M: Changes in the oxygenation of head and neck tmors during carbogen breathing. Radiat Ther Oncol 27:123-130, 1993.
67. Okunieff P, Hoeckel M, Dunphy EP, Schlenger K, Knoop C, Vaupel P: Oxygen tension distributions ar sufficient to explain the local response of human breast tumors treated with radiation alone. Int J Radiat Oncol Biol Phys 26:631-636, 1993.
68. Vaupel P, Schlenger K, Hoeckel M: Blood flow and tissue oxygenation of human tumors: An update. Adv Exp Med Biol 316:361-371, 1992.
69. Lartigau E, Randrianarivelo H, Martin L, Lern S, Thomas CD, Guichard M, Weeger P, LeRidant AM, Luboinski B, Nguyen T, Ortoli J-C, Grange F, Avril M-F, Lusinchi A, Wibault P, Haie-Meder C, Gerbaulet A, Eschwege F: Oxygen tension measurements in human tumors: The Institut Gustave-Roussy experience. Radiat Oncol Invest 1:285-291, 1994.
70. Brizel DM, Rosner GL, Harrelson J, Prosnitz LR, Dewhirst MW: Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 30(3):635-642, 1994.
71. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 29(3):427-431, 1994.
72. Brizel DM, Rosner GL, Prosnitz LR, Dewhirst MW: Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervical carcinomas, and lymph node metastases. Int J Radiat Oncol Biol Phys 32(4):1121-1125, 1995.
73. Viau A, Abuchowski A, Greenspan S, Davis F: Safety evaluation of free radical scavengers PEG-catalase and PEG-superoxide dismutase. J Free Radic Biol Med 2(4):283-288, 1986.